Venetoclax‐enhanced reduced‐intensity conditioning in older patients aged ≥55 years with high‐risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70690 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Jie Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Transplantation Conditioning, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, Bethune Charitable Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Reduced‐intensity conditioning (RIC) is associated with a high relapse rate in high‐risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo‐HSCT). It remains unclear whether venetoclax, an anti‐leukaemic agent, can enhance RIC efficacy. A prospective, single‐arm, phase 2 trial enrolled patients with high‐risk AML or MDS, aged ≥55 years, who underwent allogeneic peripheral blood stem cell transplantation (allo‐PBSCT). All patients received venetoclax‐enhanced RIC (VEN‐RIC), comprising venetoclax, busulfan, fludarabine, cytarabine and low‐dose total body irradiation (TBI). Fifty patients (median age 62) were enrolled. At a median follow‐up of 14.9 months, the 1‐year progression‐free survival (PFS) was 72.5%, while 1‐year overall survival (OS) and graft‐versus‐host disease/relapse‐free survival (GVHD/GRFS) were 73.8% and 56.9% respectively. The 1‐year cumulative incidence of relapse and non‐relapse mortality were 16.8% and 10.6%. The 180‐day cumulative incidence of acute GVHD was 22.9%, while the 1‐year cumulative incidence of chronic GVHD was 25.8%. Multivariable analysis showed TP53 mutation was the strongest predictor of worse OS, PFS and GRFS, as well as higher relapse. We conclude that VEN‐RIC is feasible and associated with encouraging survival and a manageable safety profile, warranting confirmation in randomized studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Chongmei Huang, Yu Cai, Liping Wan
Förderung
- Shanghai Municipal Health Commission
- Bethune Charitable Foundation
- National Natural Science Foundation of China
Zitieren
APA
Gao, J., Qiu, H., Tong, Y., Huang, C., Dong, B., Niu, J., Zhou, K., Cai, Y., Wan, L., Song, X., & Yang, J. (2026). Venetoclax‐enhanced reduced‐intensity conditioning in older patients aged ≥55 years with high‐risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study. British Journal of Haematology. https://doi.org/10.1111/bjh.70690
Vancouver
Gao J, Qiu H, Tong Y, Huang C, Dong B, Niu J, et al. Venetoclax‐enhanced reduced‐intensity conditioning in older patients aged ≥55 years with high‐risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study. British Journal of Haematology. 2026. doi:10.1111/bjh.70690
BibTeX
@article{Gao2026,
author = {Gao, Jie and Qiu, Huiying and Tong, Yin and Huang, Chongmei and Dong, Baoxia and Niu, Jiahua and Zhou, Kun and Cai, Yu and Wan, Liping and Song, Xianmin and Yang, Jun},
title = {Venetoclax‐enhanced reduced‐intensity conditioning in older patients aged ≥55 years with high‐risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70690}
}
EUVIMED